TY - JOUR
T1 - A framework for standardised tissue sampling and processing during resection of diffuse intracranial glioma
T2 - joint recommendations from four RANO groups
AU - Karschnia, Philipp
AU - Smits, Marion
AU - Reifenberger, Guido
AU - le Rhun, Emilie
AU - Ellingson, Benjamin M.
AU - Galldiks, Norbert
AU - Kim, Michelle M.
AU - Huse, Jason T.
AU - Schnell, Oliver
AU - Harter, Patrick N.
AU - Mohme, Malte
AU - Expert Rater Panel
AU - Aldape, Kenneth
AU - Baehring, Joachim M.
AU - Bello, Lorenzo
AU - Brat, Daniel J.
AU - Cahill, Daniel P.
AU - Chung, Caroline
AU - Colman, Howard
AU - Dietrich, Jorg
AU - Drummond, Katharine
AU - Esquenazi, Yoshua
AU - Gerstner, Elizabeth R.
AU - Furtner, Julia
AU - Garibotto, Valentina
AU - Kaufmann, Timothy J.
AU - Komori, Takashi
AU - Kotecha, Rupesh
AU - Liau, Linda M.
AU - Lupo, Janine M.
AU - Minniti, Giuseppe
AU - Narita, Yoshitaka
AU - Niyazi, Maximilian
AU - Perry, Arie
AU - Preusser, Matthias
AU - Rudà, Roberta
AU - Sanai, Nader
AU - Schmidt, Nils-Ole
AU - Steinbach, Joachim P.
AU - Thust, Stefanie C.
AU - Tolboom, Nelleke
AU - van der Hoorn, Anouk
AU - van der Vaart, Thijs
AU - Verger, Antoine
AU - Vik-Mo, Einar Osland
AU - Watts, Colin
AU - Westphal, Manfred
AU - Wesseling, Pieter
AU - Young, Jacob S.
AU - von Baumgarten, Louisa
AU - Albert, Nathalie L.
N1 - Publisher Copyright: © 2023 Elsevier Ltd
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Surgical resection represents the standard of care for people with newly diagnosed diffuse gliomas, and the neuropathological and molecular profile of the resected tissue guides clinical management and forms the basis for research. The Response Assessment in Neuro-Oncology (RANO) consortium is an international, multidisciplinary effort that aims to standardise research practice in neuro-oncology. These recommendations represent a multidisciplinary consensus from the four RANO groups: RANO resect, RANO recurrent glioblastoma, RANO radiotherapy, and RANO/PET for a standardised workflow to achieve a representative tumour evaluation in a disease characterised by intratumoural heterogeneity, including recommendations on which tumour regions should be surgically sampled, how to define those regions on the basis of preoperative imaging, and the optimal sample volume. Practical recommendations for tissue sampling are given for people with low-grade and high-grade gliomas, as well as for people with newly diagnosed and recurrent disease. Sampling of liquid biopsies is also addressed. A standardised workflow for subsequent handling of the resected tissue is proposed to avoid information loss due to decreasing tissue quality or insufficient clinical information. The recommendations offer a framework for prospective biobanking studies.
AB - Surgical resection represents the standard of care for people with newly diagnosed diffuse gliomas, and the neuropathological and molecular profile of the resected tissue guides clinical management and forms the basis for research. The Response Assessment in Neuro-Oncology (RANO) consortium is an international, multidisciplinary effort that aims to standardise research practice in neuro-oncology. These recommendations represent a multidisciplinary consensus from the four RANO groups: RANO resect, RANO recurrent glioblastoma, RANO radiotherapy, and RANO/PET for a standardised workflow to achieve a representative tumour evaluation in a disease characterised by intratumoural heterogeneity, including recommendations on which tumour regions should be surgically sampled, how to define those regions on the basis of preoperative imaging, and the optimal sample volume. Practical recommendations for tissue sampling are given for people with low-grade and high-grade gliomas, as well as for people with newly diagnosed and recurrent disease. Sampling of liquid biopsies is also addressed. A standardised workflow for subsequent handling of the resected tissue is proposed to avoid information loss due to decreasing tissue quality or insufficient clinical information. The recommendations offer a framework for prospective biobanking studies.
UR - http://www.scopus.com/inward/record.url?scp=85175242705&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S1470-2045(23)00453-9
DO - https://doi.org/10.1016/S1470-2045(23)00453-9
M3 - Review article
C2 - 37922934
SN - 1470-2045
VL - 24
SP - e438-e450
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 11
ER -